Journal of Clinical Medicine (Feb 2020)

Nucleoside Diphosphate Kinase B Contributes to Arrhythmogenesis in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes from a Patient with Arrhythmogenic Right Ventricular Cardiomyopathy

  • Fanis Buljubasic,
  • Ibrahim El-Battrawy,
  • Huan Lan,
  • Santosh K. Lomada,
  • Anupriya Chatterjee,
  • Zhihan Zhao,
  • Xin Li,
  • Rujia Zhong,
  • Qiang Xu,
  • Mengying Huang,
  • Zhenxing Liao,
  • Siegfried Lang,
  • Lukas Cyganek,
  • Xiaobo Zhou,
  • Thomas Wieland,
  • Martin Borggrefe,
  • Ibrahim Akin

DOI
https://doi.org/10.3390/jcm9020486
Journal volume & issue
Vol. 9, no. 2
p. 486

Abstract

Read online

Background: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a rare, inheritable cardiac disorder characterized by ventricular tachyarrhythmias, progressive loss of cardiomyocytes with fibrofatty replacement and sudden cardiac death. The exact underlying mechanisms are unclear. Methods: This study investigated the possible roles of nucleoside diphosphate kinase B (NDPK-B) and SK4 channels in the arrhythmogenesis of ARVC by using human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). Results: In hiPSC-CMs from a patient with ARVC, the expression levels of NDPK-B and SK4 channels were upregulated, the cell automaticity was increased and the occurrence rate of arrhythmic events was enhanced. Recombinant NDPK-B applied into hiPSC-CMs from either healthy donors or the patient enhanced SK4 channel current (ISK4), cell automaticity and the occurrence of arrhythmic events, whereas protein histidine phosphatase 1 (PHP-1), a counter actor of NDPK-B, prevented the NDPK-B effect. Application of PHP-1 alone or a SK4 channel blocker also reduced cell automaticity and arrhythmic events. Conclusion: This study demonstrated that the elevated NDPK-B expression, via activating SK4 channels, contributes to arrhythmogenesis in ARVC, and hence, NDPK-B may be a potential therapeutic target for treating arrhythmias in patients with ARVC.

Keywords